The founder of the controversial Dr.
Goodenowe Restorative Health Center has announced he’s in the final stages of building a drug manufacturing lab and a clinical trials centre in Moose Jaw, Sask., as part of a plan that will inspire a “health revolution" — an "Alzheimer's eradication program." Dayan Goodenowe made the announcement on Feb.
13, at a five-star golf and spa resort in southern California where his associate introduced him as “an incredible genius” and “our real life superhero.” “I like to call him the disease Pokémon hunter,” the associate said.
"Because he's developed technology to truly catch them all." Goodenowe then took to the stage, proclaiming that "Alzheimer's can be beaten." "We know what causes it.
We know who gets it and we know who does not get it.
Alzheimer's is not to be feared," he said, quoting from his 2021 book, Breaking Alzheimer's: A 15 Year Crusade to Expose the Cause and Deliver the Cure.
"We must now continue on to identify and break the barriers that pertain to the implementation of an Alzheimer's eradication program." His audience was there to learn about the benefits of signing up for membership in Goodenowe's Elite Practitioner Program.
He told them this was their chance to get in "on the ground level" with a treatment that will become "the standard of care" around the world.
That treatment is his supplement: ProdromeNeuro.
Goodenowe announced he is launching a process which he thinks will lead to its approval by the U.S.
Food and Drug Administration (FDA) as a drug treatment for Alzheimer's.
He said ProdromeNeuro will be manufactured at his pharmaceutical plant and will be tested at his clinical trials centre, both of which are in their final stage of construction in Moose Jaw.
"And there's really no reasonable expectation for us not to have a fully FDA-approved drug by 2029," he told the crowd.
"I've been pretty good at predicting the future in the past." He said that there is one infuriating fact at the heart of this story: "this really should have been on the market almost 10 years ago." But he said his previous company which was leading that effort, Phenomonome Discoveries Inc.
(PDI), was blown up by some of his former investors and employees, who he has described as “greedy, soulless bastards." He told his California audience that even though PDI was "worth between $500 million and a billion dollars at fire sale prices," it was unjustly snatched from him for less than $10 million.
"So for 10 years, life saving technologies have been basically lost," he said.
'He's in his own reality' Goodenowe's announcement is just the latest in a series of claims he has made over the years about supplements he has invented and the impact they can have on preventing, treating and curing diseases, from ALS to cancer to Alzheimer's.
While he makes these claims with great certainty, those who have worked with him believe he can't be relied on to speak truthfully.
Peter Blaney, who invested $12 million in PDI, holding 25 per cent of its shares, is one of the people Goodenowe described as "greedy, soulless bastards." Goodenowe made that statement in a letter he sent to all of the company's investors on Nov.
Blaney said he has a very clear memory of reading that letter, in which Goodenowe also said "it is extraordinarily clear that the only intent of these players is to destroy this company by any and all means possible up to and including criminal behaviour." "We were questioning his sanity," said Blaney, speaking about himself and other PDI investors.
In that same letter, Goodenowe also claimed that he had the cure for Alzheimer's and cancer, saying "this is not some mythical or theoretical time in the future.
This is NOW." "They're nonsense claims.
I mean that's snake and oil salesman," said Blaney.
Goodenowe also claimed he was conducting a clinical trial, at that very moment, on a life-saving drug for another exceedingly rare disease.
"He's not right," Blaney said.
"He's in his own reality." Investigations and lawsuits Goodenowe and ProdromeNeuro have been prominent in the news for months now.
Earlier this year, the FDA issued a warning letter, saying Goodenowe put the health of research subjects at risk when he ran a study of Alzheimer's patients, published in 2022, using ProdromeNeuro without FDA approval.
Goodenowe and his supplement were also the focus of a series of CBC investigations last year.
ProdromeNeuro is part of a program that he claimed had a 100 per cent success rate in stopping and reversing ALS symptoms.
However, the ALS Society of Canada says there is no known cure or treatment that appreciably slows the progress of the fatal disease.
Hard to swallow: ALS patients cast doubt on Moose Jaw scientist's claim to halt disease progression Goodenowe is not a medical doctor and his facility, the Dr.
Goodenowe Restorative Health Center, is not regulated by any government entity.
ALS patients or their families, who paid him tens of thousands of dollars to be in the program, told CBC their ALS symptoms continued to worsen while in the program and afterward.
Following CBC’s reporting, Moose Jaw city police and the province’s consumer affairs authority launched investigations into Goodenowe’s organization in response to complaints.
American ALS patient died alone after paying $84K US in pursuit of healing at controversial Sask.
facility Politicians calling for investigations of controversial Moose Jaw health centre following CBC report Goodenowe is suing CBC for its reporting, alleging it is defamatory.
He has also sued one of the people featured in CBC's stories, Geoff Sando, an ALS patient from California.
Goodenowe alleges Sando and his wife defamed him and drove potential clients away from his business.
Geoff Sando died this past Thursday.
Man behind controversial Sask.
facility threatens NDP MLA with lawsuit, files suit against critic In addition, he has threatened to sue the Saskatchewan NDP and the ALS Society of Saskatchewan for defamation.
In a letter to supporters earlier this year, he said that the NDP and the CBC were likely conspiring with the ALS drug industry and the ALS association to discredit his business because it is a "direct threat to the ALS industry." Blaney, who lives in Ontario, said watching this unfold from a distance has brought back painful memories.
"I was disappointed to hear that he was still going forward with a new clinic and new lies and new promises and new victims," Blaney said.
He describes his investment in PDI and the trust he placed in Goodenowe as "one of the biggest mistakes of my career." He said he lost all $12 million — money he placed on behalf of clients.
"You wear that forever," Blaney said.
'It's not that complicated' At his Feb.
13 announcement, Goodenowe told his audience that even though the path ahead seems daunting, it's really not.
It will all be handled through his new drug development company, Dietary Therapeutics.
“The FDA approval process is not that complicated.
OK?" he said.
The first step, Goodenowe said, will be to file an Investigational New Drug (IND) application with the FDA, which he said is also "not a big deal, OK?" In an IND, researchers are required to provide data showing the drug won't expose subjects to unnecessary risk.
It was Goodenowe's failure to file an IND prior to launching his 2022 study of the effects of ProdromeNeuro on Alzheimer's patients, that led the FDA to issue its warning letter.
The letter said Goodenowe's failure raised concerns about the safety of the research subjects and the "validity and integrity of the data collected." Those concerns led the journal which published his research study, Frontiers in Cell and Developmental Biology, to launch its own investigation and post a correction on the article, flagging it with an "expression of concern." When asked about this in January, Goodenowe said this was all based on a miscommunication that will "be resolved in the near future." The FDA warning remains on its site.
Goodenowe said he has decided to go down the FDA-approval path with ProdromeNeuro because it's the only way to legitimately and ethically be able to claim that your product can treat or cure disease.
He said FDA approval is also crucial for getting consumer buy-in.
"I don't care if it's FDA approved or not.
I'll just look at the data, I'll look at the papers, I'll do whatever the hell I want," he said.
But most people don't see it that way, he added.
"People will not take a supplement that could save the life of their child because it's not FDA approved.
That's the real tragedy right there," he said.
From Moose Jaw to China? The California announcement seems to be the latest step in his "$100 million Community Health Investment" announcement, which he made last April.
At that time, he promised to build a series of facilities in Moose Jaw that would "build community health by combining advanced technology with hands-on community engagement to make real and measurable differences in the lives of everyday people." Goodenowe's focus goes beyond Alzheimer's and ALS.
In December he launched a program with Autism Health Inc.
in the United States to provide education, community support and "subsidized nutritional supplementation" for children with autism.
And in February he launched a neurosupport program to support people with ADHD, anxiety, depression and brain injuries.
In October, he announced he had partnered with a Chinese firm on 1,000 rehabilitation centers and 100 “Dr.
Goodenowe-branded blood testing and digital brain imaging centers” across China.
In that news release, he said his “manufacturing facility in Moose Jaw will produce the plasmalogen precursors (Goodenowe's supplements) for importation into the Chinese market.” As part of his California talk, he continued reading from his 2021 book, Breaking Alzheimer's, in which he suggested that the tendency of the public to follow the received wisdom of experts may be a mistake.
"We rely on expert opinions because we assume they are based on facts.
But what if they're not?" he asks.
"What if all the experts are only lemmings repeating the views of previous lemmings? Whom can you believe?" The book answers, "trust yourself." But it also offers readers another alternative.
He says the discoveries he has made were just sitting in plain view.
"This obviousness, in turn, creates a natural reaction of incredulousness," he wrote.
"How is it that all our trusted experts missed this? Easily.
I am more than just any expert." Goodenowe or Goodnough? Goodenowe was born in 1969 as Dayan Goodnough, and raised in Moose Jaw.
In his book, he says he was a bit unusual from the beginning.
"My parents like to joke that I was born grown up.
I don’t remember ever being treated like a child," he wrote.
"I could drive a standard truck when I was four and a half years old." It was under the Goodnough name that, in 1994, he received his Ph.D in medical sciences with a focus on psychiatry from the University of Alberta.
Then, in October 1995, just over a year after receiving his degree, he declared bankruptcy.
He said he had $66,000 in liabilities and $16,500 in assets.
Court documents reveal that some of that debt was from Alberta, Saskatchewan and Canadian student loans — at least $20,000.
In 2002, he began publishing under the name Goodenowe, according to ScholarGPS.
From that point, that’s the name he used on all of his academic work.
Blaney said when he first invested with Goodenowe, he didn't know he used to do business under the Goodnough name and didn't know about the bankruptcy.
He said if he had known about the bankruptcy, "it might have actually scuppered the deal." Attracting investors and building trust In the early 2000s he created Phenomenome Discoveries Inc.
Its 2001....
